Gliknik
Gliknik is a privately held biopharmaceutical company dedicated to discovering and developing innovative biologics for people living with immune disorders. The company combines scientific expertise with business acumen and industry experience, focusing on creating therapies to ease human suffering caused by autoimmune diseases and cancers. With a commitment to scientific rigor, Gliknik is advancing multiple drugs in clinical trials, including GL-2045 and GL-0719, and holds a significant portfolio of intellectual property. The company aims to address unmet medical needs through cutting-edge science and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
US-12122836-B2
View DetailsFusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
US-12084482-B2
View Details
Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
US-12122836-B2
View DetailsFusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
US-12084482-B2
View DetailsProducts
GL-2045
Recombinant multimerizing Fc-based IVIg mimetic designed to reproduce the active Fc aggregate fraction of pooled human IVIg for treatment of autoimmune diseases; developed for intravenous and subcutaneous administration and intended for indications such as CIDP.
GL-0719
Recombinant Fc-fusion biologic designed to selectively inhibit the classical and lectin complement pathways while preserving alternative and terminal pathways; advanced into Phase 1 clinical evaluation to assess safety, PK/PD and complement pathway inhibition.
GL-0817
Investigational vaccine candidate developed by Gliknik, applying learnings from previous cancer therapeutic vaccines.
G207
A recombinant human Fc multimer engineered to have enhanced C1q binding and reduced Fc receptor engagement, showing efficacy in preventing complement mediated diseases in animal models.
G211
A recombinant human Fc multimer engineered to have enhanced C1q binding and reduced Fc receptor engagement, showing broad efficacy in preventing and treating complement mediated diseases in animal models.
GB4542
A fully recombinant anti-CD20 protein derived from cDNA encoding one Fab domain, two IgG1 Fc regions, the IgG2 hinge, and an isoleucine zipper, containing both homodimer and higher-order multimers. It preferentially binds CD20+ cells and shows enhanced antibody-dependent cellular cytotoxicity, phagocytosis, and complement-dependent cytotoxicity, with potential utility in autoimmune disease treatment by combining B cell depletion and tolerogenic effects.
GL-2045
Recombinant multimerizing Fc-based IVIg mimetic designed to reproduce the active Fc aggregate fraction of pooled human IVIg for treatment of autoimmune diseases; developed for intravenous and subcutaneous administration and intended for indications such as CIDP.
GL-0719
Recombinant Fc-fusion biologic designed to selectively inhibit the classical and lectin complement pathways while preserving alternative and terminal pathways; advanced into Phase 1 clinical evaluation to assess safety, PK/PD and complement pathway inhibition.
GL-0817
Investigational vaccine candidate developed by Gliknik, applying learnings from previous cancer therapeutic vaccines.
G207
A recombinant human Fc multimer engineered to have enhanced C1q binding and reduced Fc receptor engagement, showing efficacy in preventing complement mediated diseases in animal models.
G211
A recombinant human Fc multimer engineered to have enhanced C1q binding and reduced Fc receptor engagement, showing broad efficacy in preventing and treating complement mediated diseases in animal models.
GB4542
A fully recombinant anti-CD20 protein derived from cDNA encoding one Fab domain, two IgG1 Fc regions, the IgG2 hinge, and an isoleucine zipper, containing both homodimer and higher-order multimers. It preferentially binds CD20+ cells and shows enhanced antibody-dependent cellular cytotoxicity, phagocytosis, and complement-dependent cytotoxicity, with potential utility in autoimmune disease treatment by combining B cell depletion and tolerogenic effects.
Expertise Areas
- Immune-modulating biologics development
- Fc engineering and multimeric Fc design
- Clinical trial management (Phase 1 execution)
- Preclinical in vivo disease modeling
Key Technologies
- Recombinant protein expression
- Fc-fusion and multimerizing Fc engineering
- Parenteral formulation for IV and SC delivery
- Rodent in vivo disease models